Publications by authors named "Joyce Marques de Almeida"
Article Synopsis
- The COVID-19 pandemic has severely affected individuals with hematological malignancies due to their weakened immune systems, resulting in higher mortality rates and severe outcomes.
- Data from the EPICOVIDEHA registry, which compiles COVID-19 cases from these patients worldwide, was collected from 2020 to 2022, including 8,767 cases from 152 centers across 41 countries.
- Findings show a significant drop in critical infections and overall mortality rates, but hospitalization (especially in ICU) remains a serious risk factor; vaccination is linked to better survival outcomes, highlighting the need for ongoing monitoring and support for these patients.
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world.
View Article and Find Full Text PDFArticle Synopsis
- - Patients who had CD19-directed CAR T-cell therapy remain highly susceptible to viral infections, especially with COVID-19, which showed a 31% overall mortality rate in the study population.
- - Those infected with the Omicron variant had a significantly lower mortality risk (7%) compared to earlier variants (58%).
- - Vaccination and monoclonal antibody treatment were found to improve outcomes, with a marked reduction in mortality (from 32% to 0%) for those treated with monoclonal antibodies, indicating better survival rates for CAR T-cell recipients over time.
Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients.
Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022.
The scope of this study was to evaluate the functional capacity and analyze the characteristics associated with the disability of elderly individuals attended in a Family Health Strategy Unit in Montes Claros in the state of Minas Gerais. The Lawton and Brody scale and the Katz scale were used and then analyzed using multinomial logistic regression. 286 elderly individuals were interviewed with ages ranging from 60 to 103 years and a mean age of 71.
View Article and Find Full Text PDF